{"filings":[{"id":77522,"accession_number":"0001104659-26-060686","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-05-14T11:10:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cypherpunk Q1 net loss $77.2M as $77.6M unrealized ZEC loss hits earnings","event_type":"earnings","confidence":"high","bullets":["Net loss $77.2M vs $15.4M YoY; $77.6M unrealized loss on ZEC marked to market.","ZEC price fell from $508.09 to $240.47 in Q1; ZEC holdings valued at $73.8M on March 31.","ZEC treasury increased to 314,185.70 ZEC (1.88% of circulating supply), avg cost $337.86.","Invested $5M into Zcash Open Development Labs (ZODL) alongside a16z, Coinbase, Paradigm.","FDA granted Fast Track designation for sirexatamab in DKK1-high metastatic colorectal cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93291,"accession_number":"0001104659-26-041981","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Four directors to retire from Cypherpunk board at 2026 annual meeting","event_type":"leadership","confidence":"high","bullets":["Drs. Mirabelli, Loscalzo, Schilsky, and Cavanaugh resign effective immediately before the 2026 Annual Meeting.","Mirabelli and Loscalzo were Class III directors; Schilsky and Cavanaugh were Class I directors.","None of the departures are due to any disagreement with the company on operations, policies, or practices.","No replacements announced; the Board thanked each director for their service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104784,"accession_number":"0001104659-26-028558","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cypherpunk reports FY2025 net income of $4.8M; ZEC treasury at $147.4M","event_type":"earnings","confidence":"high","bullets":["Net income of $4.8M vs net loss of $67.8M in 2024; driven by $50.4M unrealized gain on ZEC holdings.","Cash $14.0M; ZEC treasury 294,743.10 ZEC (1.78% of supply) at avg cost $335.89, valued $147.4M at year-end.","Closed $58.88M private placement led by Winklevoss Capital in October 2025.","Invested $5M in ZODL, developer of Zodl Zcash wallet, alongside a16z, Coinbase, Paradigm.","Sirexatamab in DKK1-high CRC showed ORR 44% vs 15.8% control; mOS not reached vs 9.66 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104783,"accession_number":"0001104659-26-025194","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cypherpunk Technologies receives Nasdaq minimum bid price deficiency letter; must regain compliance by Aug 31, 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Cypherpunk that its common stock closing bid price was below $1.00 for 30 consecutive business days.","Company has 180 days, until August 31, 2026, to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.","If compliance not met, Cypherpunk may qualify for a second 180-day period if it meets other Nasdaq initial listing standards.","The notice does not currently affect listing or trading on the Nasdaq Capital Market.","Management is considering options including a reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121066,"accession_number":"0001104659-25-125224","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Cypherpunk grants 5.45M RSUs to consultant CoinXit; cancels prior award","event_type":"other_material","confidence":"high","bullets":["Granted 5,448,157 RSUs under 2025 Equity Incentive Plan; cancels prior 2,411,700 RSUs under 2022 Plan.","RSUs vest 12/36 on Oct 8, 2026, then 1/36 monthly, subject to continuous service.","Grant satisfies all remaining RSU obligations under November 2025 Consulting Agreement with CoinXit.","CoinXit's sole director Khing Oei serves as Chairman of the Board and is a Winklevoss Treasury designee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121065,"accession_number":"0001104659-25-125039","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cypherpunk buys additional 56,418 ZEC for ~$29M, total holdings reach 290,063 ZEC (1.76% of supply)","event_type":"other_material","confidence":"high","bullets":["Purchased 56,418.09 ZEC at $514.02/ZEC for ~$29 million.","Total ZEC holdings now 290,062.67, acquired at cumulative avg $334.41/ZEC.","Holdings represent ~1.76% of total circulating Zcash network supply.","CIO confirms goal to accumulate 5% of Zcash network.","Acquisition follows prior strategic purchases over preceding months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121064,"accession_number":"0001104659-25-121566","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02","5.07","5.03","8.01","9.01"],"status":"ready","headline":"Cypherpunk Tech stockholders approve 2025 equity plan, charter amendment, reverse split; Nasdaq compliance regained","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2025 Equity Incentive Plan covering up to 31,454,785 shares of common stock.","Charter amendment increased authorized shares from 250M to 500M (490M common, 10M preferred).","Reverse stock split approved with 36,314,864 votes for, 4,935,206 against, 691,181 abstain.","Private placement issuance approved with 17,403,379 votes for, 1,361,238 against, 154,144 abstain.","Nasdaq notified company on Dec 11, 2025 that it regained compliance with minimum bid price rule (Listing Rule 5550(a)(2))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121063,"accession_number":"0001104659-25-114435","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cypherpunk Technologies enters waiver agreement with Winklevoss Capital to free shares for $200M ATM program","event_type":"other_material","confidence":"high","bullets":["Cypherpunk Technologies (CYPH) signed a waiver agreement with Winklevoss Capital on November 19, 2025, modifying the October 8, 2025 common warrant.","Winklevoss waived the share reservation covenant for 57,182,378 warrant shares to allow their issuance under the company's $200 million ATM equity offering program.","Winklevoss cannot exercise the warrant for those restricted shares until authorized common stock reaches 490 million shares or a reverse stock split of at least 1:5 occurs.","The waiver applies only to the 57,182,378 restricted shares; other warrant shares remain unaffected.","The agreement supports Cypherpunk's ability to raise capital through its existing ATM facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121062,"accession_number":"0001104659-25-113698","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cypherpunk buys additional $18M of Zcash, now holds 1.43% of network","event_type":"other_material","confidence":"high","bullets":["Purchased 29,869.29 ZEC for $18M at average price $602.63/ZEC on November 18, 2025.","Total ZEC holdings now 233,644.56 at average cost $291.04, representing 1.43% of the Zcash network.","Initial acquisition of 203,775.27 ZEC for $50M at $245.37/ZEC was disclosed November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121071,"accession_number":"0001104659-25-110341","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cypherpunk Technologies (fka Leap Therapeutics) enters up to $200M ATM equity sales agreement with Cantor Fitzgerald","event_type":"other_material","confidence":"high","bullets":["Company entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell up to $200M of common stock.","Cantor will receive a commission of up to 3.0% of gross proceeds from each sale.","Sales will be made 'at the market' under existing shelf registration statement (File No. 333-278015).","Company has no obligation to sell any shares and can suspend or terminate agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121070,"accession_number":"0001104659-25-109820","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.03","1.01","2.02","5.02","7.01","8.01"],"status":"ready","headline":"Leap Therapeutics rebrands as Cypherpunk, buys $50M ZEC, appoints new leaders","event_type":"other_material","confidence":"high","bullets":["Company renamed Cypherpunk Technologies; stock ticker changes from LPTX to CYPH on Nov 13, 2025.","Acquired 203,775 ZEC for $50M ($245.37 avg) under new digital-asset treasury strategy.","Khing Oei appointed Chairman; Will McEvoy appointed CIO and director; Oei's CoinXit Ltd. engaged as consultant.","Awarded 2,411,700 RSUs to CoinXit and 5,616,906 RSUs to McEvoy (subject to conditions), plus RSUs to directors/employees.","Reported Q3 2025 financial results (press release furnished as Exhibit 99.2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121069,"accession_number":"0001104659-25-100646","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025","event_type":"other_material","confidence":"high","bullets":["In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).","In DKK1-high (upper quartile, n=44): mPFS 9.36 vs 5.88 mo (HR 0.46, p=0.017); mOS not reached vs 9.66 mo (HR 0.17, p<0.001).","Full ITT (n=188): mPFS 9.2 vs 8.3 mo (HR 0.84, p=0.171); ORR 35.1% vs 26.6%.","Sirexatamab well tolerated; TEAE profile similar between arms.","Leap plans to engage regulators on registrational path for sirexatamab in CRC; supported by recent financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121068,"accession_number":"0001104659-25-098082","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","3.02","7.01","8.01"],"status":"ready","headline":"Leap Therapeutics closes $58.9M private placement led by Winklevoss Capital to pursue digital asset treasury","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$58.88M from sale of 15.2M shares, 80.8M pre-funded warrants, and 72.0M common warrants.","Winklevoss Capital leads the deal; gets right to nominate two board members, one of whom will serve as chair.","Proceeds to fund a digital asset treasury strategy and continue development of FL-501 and sirexatamab.","Common warrants priced at $0.5335/share, 10-year term; pre-funded warrants exercisable at $0.001/share with no expiration.","Parcrest serves as placement agent; receives $1.5M fee ($1M cash plus warrants for 4M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121067,"accession_number":"0001104659-25-096966","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Leap Therapeutics raises $58.9M in PIPE led by Winklevoss Capital, adopts digital asset treasury strategy","event_type":"other_material","confidence":"high","bullets":["$58,888,888 in cash commitments for PIPE offering at $0.61439 per unit, led by Winklevoss Capital.","Issues 95.8M shares/pre-funded warrants and 71.9M warrants exercisable at $0.5335 per share.","Closing expected October 8, 2025; Winklevoss Capital to nominate two board members, one as chair.","Proceeds to fund digital asset treasury strategy and continued development of FL-501 and sirexatamab.","Company reaffirms pursuit of existing biotech pipeline alongside new digital asset strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137692,"accession_number":"0001410578-25-002072","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Leap Therapeutics gets Nasdaq bid price extension to March 9, 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day compliance period until March 9, 2026, for minimum $1.00 bid price.","Initial 180-day period ended Sept. 8, 2025; company met all other listing standards except bid price.","Company may implement a reverse stock split to regain compliance.","No assurance of regaining compliance; delisting could follow if not cured by March 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137691,"accession_number":"0001104659-25-078077","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.","R&D expenses $10.5M (down from $17.9M); G&A $1.8M (down from $3.4M); restructuring charge $4.5M.","Board initiated review of strategic alternatives; engaged Raymond James as financial advisor.","Workforce reduced ~75% to preserve capital; majority of severance costs in Q3/Q4 2025.","Updated Phase 2 DeFianCe data showed statistically significant benefit on ORR and PFS in certain CRC subgroups."],"consensus_eps_estimate":-0.2958,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155075,"accession_number":"0001104659-25-061385","cik":1509745,"company_name":"CYPHERPUNK TECHNOLOGIES INC.","ticker":"CYPH","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["2.05","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Leap reports sirexatamab PFS benefit in CRC subgroups; workforce cut 75%, strategic review","event_type":"other_material","confidence":"high","bullets":["DeFianCe study: in high-DKK1 pts (upper quartile), median PFS 9.36 vs 5.88 mo (HR 0.47, p=0.024); ORR 44% vs 15.8% (p=0.015).","VEGF-naïve pts: median PFS 11.2 vs 8.34 mo (HR 0.61, p=0.038); ORR 55.1% vs 32.6% (p=0.012).","Full population ORR by BICR 33% vs 20.2% (p=0.0203); median PFS 9.2 vs 8.31 mo (HR 0.84, p=0.1749) not significant.","Board initiates strategic alternatives review; Raymond James engaged as advisor; workforce reduction of ~75% with $3.2M severance costs.","COO (Lawlor) terminated June 30, CMO (Sirard) terminated July 31; cash $32.7M (Mar 31)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}